In the multicenter, phase III, noninferiority PROSPECT trial, preoperative #FOLFOX was noninferior to preoperative chemoradiotherapy with respect to disease-free survival in patients with locally advanced #rectal cancer who were eligible for sphincter-sparing surgery. 
In this open label, randomized trial, 1194 eligible patients with locally advanced rectal cancer defined as having T2 node-positive, T3 node-negative, or T3 node-positive disease who were candidates for sphincter-sparing surgery. Patients were randomized to either neoadjuvant FOLFOX (with chemoradiotherapy given only if the primary tumor decreased in size by <20% or if FOLFOX was discontinued because of side effects)  or chemoradiotherapy administered as 5,040 cGy over 5.5 weeks with concurrent chemotherapy with either oral capecitabine or intravenous 5-FU.
The primary end point was disease-free survival. Noninferiority would be claimed if the upper limit of the two-sided 90.2% confidence interval of the hazard ratio for disease recurrence or death did not exceed 1.29. Secondary end points included overall survival, local recurrence, complete pathological resection.
After median follow-up of 58 months, FOLFOX was noninferior to chemoradiotherapy for  DFS (HR= 0.92; (90% CI 0.74 to 1.14); P=0.005 for noninferiority). 5-year DFS was 80.8%  in the FOLFOX group and 78.6% in the CRT group. Additionally, Both arms had similar OS and Local recurrence rates, 5year OS was 89.5% and 90.2% in the FOLFOX and CRT arms respectively (HR=1.04; 95% CI, 0.74 to 1.44). 5-year local recurrence free survival was 98.2% and 98:4% in both arms respectively (HR=1.18; 95% CI, 0.44 to 3.16). In the FOLFOX group, 53 patients (9.1%) received preoperative chemoradiotherapy and 8 (1.4%) received postoperative chemoradiotherapy."